medigraphic.com
ISSN 1561-3046 (Electronic)

2021, Number 4

<< Back Next >>

Rev Cub Med Mil 2021; 50 (4)

Survival of an elderly patient with lung cancer treated with first-line chemotherapy

Quintana BOA, Vallejos GRE, Olmos SRC, Salvador CJF, Salinas PJL

Language: Spanish
References: 11
Page:
PDF size: 237.14 Kb.


ABSTRACT

Introduction: Lung cancer is taking an increasing toll on the older population as life expectancy increases. However, the efficacy of chemotherapy is difficult to establish and the prognosis of these patients is severe. Objective: Report a case of an older adult patient with advanced non-small cell lung cancer with prolonged survival who received only first-line chemotherapy. Case report: A 71-year-old non-smoker patient diagnosed with advanced non-small cell lung cancer, adenocarcinoma subtype, with pleural involvement. He started treatment with carboplatin 5 AUC and gemcitabine 1,1 g. In the ninth cycle, reduction of pulmonary nodules was found, but he also had metastases at the D6-D7 level. He started the second line of treatment with carboplatin 5,4 AUC, paclitaxel 200 mg and zolendronic acid at a dose of 4,0 mg. Due to adverse events, the treatment was changed to vinorelbine 2,5 g and zolendronic acid 4.0 mg. After two cycles, the patient died, reaching 21 months of overall survival, only with chemotherapy. Conclusion: The treatment of the older adult patient with lung cancer is challenging. In the present chemotherapy treatment, the patient was able to achieve 21 months of overall survival, despite the fact that he was not molecularly characterized.


REFERENCES

  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 [acceso: 31/07/2020]; 68(6):394-424. Disponible en: Disponible en: https://acsjournals.onlinelibrary.wiley.com/doi/full/10.3322/caac.21492

  2. Jennens RR, Giles GG, Fox RM. Increasing underrepresentation of elderly patients with advanced colorectal or non-small-cell lung cancer in chemotherapy trials. Intern Med J. 2006 [acceso: 01/01/2020]; 36(4):216-20. Disponible en: Disponible en: https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1445-5994.2006.01033.x

  3. Davidoff AJ, Tang M, Seal B, Edelman MJ. Chemotherapy and survival benefit in elderly patients with advanced non - small-cell lung cancer. J Clin Oncol. 2010 [acceso: 31/01/2020]; 28(13):2191-7. Disponible en: Disponible en: https://ascopubs.org/doi/10.1200/JCO.2009.25.4052?url_ver=Z39.882003&rfr_

  4. Takayuki N, Keiko T, Junji U, Yoshiko K, Nobuyo T, Tadaaki Y, et al. Advanced Non-Small-Cell Lung Cancer in Elderly Patients: Patient Features and Therapeutic Management. Biomed Res Int. 2018 [acceso: 03/03/2020];18:8. Disponible en: Disponible en: https://www.hindawi.com/journals/bmri/2018/8202971/

  5. Okamoto T, Maruyama R, Shoji F, Asoh H, Ikeda J, Miyamoto T, et al. Long-term survivors in stage IV non-small cell lung cancer. Lung Cancer. 2005 [acceso: 04/04/2020]; 47(1):85-91. Disponible en: Disponible en: https://www.lungcancerjournal.info/article/S0169-5002(04)00301-0/fulltext

  6. Satoh H, Ishikawa H, Ohara G, Kagohashi K, Kurishima K, Ohtsuka M, et al. Long-term survivors after chemotherapy in advanced non-small cell lung cancer. Anticancer Res. 2007 [acceso: 03/07/2020]; 27(6 C):4457-60. Disponible en: Disponible en: http://ar.iiarjournals.org/content/27/6C/4457.long

  7. Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Survival determinants in extensive-stage non-small-cell lung cancer: The southwest oncology group experience. J Clin Oncol. 1991 [acceso: 04/10/2020]; 9(9):1618-26. Disponible en: Disponible en: https://ascopubs.org/doi/pdf/10.1200/JCO.1991.9.9.1618

  8. Jara Exebio JJ, Cabrera Sandoval RN, Amaro Palomino JK, Revilla López JC. Adenocarcinoma pulmonar metastásico con evolución favorable al tratamiento con ITK-EGFR en un paciente fumador Metastaticlung adenocarcinoma favorable outcomewith ITK-EGFR treatment in a smoker. An Fac Med. 2011[acceso: 02/09/2020]; 76:199-202. Disponible en: Disponible en: http://www.scielo.org.pe/pdf/afm/v76n2/a14v76n2.pdf

  9. Castro C, Cardona F, Revéiz L, Serrano J, Carranza H, Vargas C, et al. Cáncer de pulmón de célula no pequeña metastásico. Acta Médica Colomb. 2010[acceso:04/04/2020]; 35(2):53-81. Disponible en: Disponible en: http://www.scielo.org.co/pdf/amc/v35n2/v35n2a04.pdf

  10. Kaira K, Takahashi T, Murakami H, Tsuya A, Nakamura Y, Naito T, et al. Long-term survivors of more than 5 years in advanced non-small cell lung cancer. Lung Cancer. 2010 [acceso: 05/07/2020]; 67(1):120-3. Disponible en: Disponible en: https://www.lungcancerjournal.info/article/S0169-5002(09)00137-8/fulltext

  11. Lin JJ, Cardarella S, Lydon CA, Dahlberg SE, Jackman DM, Jänne PA, et al. Five-Year Survival in EGFR -Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs. J Thorac Oncol .2016 [acceso: 05/05/2020]; 11(4):556-65. Disponible en: Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S1556086415002658




2020     |     www.medigraphic.com